Skip to content

Short Versus Long Protocol for IVF and IVF+ICSI

Short Versus Long IVF-treatment. A Prospective, Consecutive and Randomized Comparative Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00756028
Acronym
KvL
Enrollment
1099
Registered
2008-09-19
Start date
2009-01-31
Completion date
2015-12-31
Last updated
2016-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Live Birth, Ovarian Hyperstimulation Syndrome, Quality of Life

Keywords

OHSS, quality of life, IVF, ICSI, GnRH-agonist, GnRH-antagonist

Brief summary

Purpose: Comparing a GnRH agonist and an antagonist protocol for IVF/ICSI with regard to 1. frequency of ovarian hyperstimulation syndrome (OHSS) (1. outcome measure) 2. quality of life (2. outcome measure) 3. live birth rate (2. outcome measure) 4. gene expression profiles of granulosa and cumulus cells, and concentrations of estradiol and vascular endothelial growth factor in follicular fluid(not only compared between GnRH agonist and antagonist protocol, but also between patients with OHSS and no OHSS and patients becoming pregnant and not becoming pregnant (2. outcome measure), and 5. number of oocytes removed per treatment, number of embryo transfers per treatment and number of spontaneous abortions per treatment (these three parameters are tertiary outcome measures). In addition to the above mentioned efficacy outcome measures the safety outcome measure frequency of known side-effects will be compared between the two protocols.

Detailed description

Patients: 1100 patients are randomized prospectively to either treatment. Stratification: =\<36 y/\>36 y, IVF/ICSI, and treatment centre. Methods: OHSS is quantified by consecutive measurements of weight, abdominal diameter, ultrasound measurements of ascites and ovarian volume, paraclinical parameters, and by a systematic patient questionnaire. Furthermore it is registered if the patients have been hospitalized and/or have had ascites drainage performed due to OHSS. Data from the first 100 patients are used together with Golans OHSS-classification, to make a more precise definition of OHSS. This definition is applied prospectively on data from the remaining patients. Quality of life is gauged by a questionnaire. Child birth rate is ascertained by a pregnancy response questionnaire and by obtaining data from the Danish National Birth Registry. Statistics: The study is designed to be able to show a 50% reduction of OHSS comparing short to long protocol.

Interventions

DRUGPatients receiving short protocol IVF/ICSI-treatment.

Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day

DRUGLong protocol

Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)

Sponsors

Peter Hornnes, MD, DMSc
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 39 Years
Healthy volunteers
No

Inclusion criteria

* All patients referred for infertility receiving their first IVF or IVF+ICSI treatment

Exclusion criteria

* Previous IVF or IVF+ICSI-treatment * Uterine anomalies * It is necessary to perform direct sperm aspiration from husband's/partner's testicles * Allergy to one of the intervention products * Patient is 40 years or above

Design outcomes

Primary

MeasureTime frame
Frequency of Ovarian Hyperstimulation Syndrome (OHSS)3 years

Secondary

MeasureTime frame
Quality of life during treatment3 years
Live births3 years
Gene expression profiles of granulosa and cumulus cells3 years
Estradiol and vascular endothelial growth factor concentrations in follicular fluid.3 years

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026